Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come.
Novartis gets emricasan’s rights...
Heat Biologics Inc (NASDAQ:HTBX) recently said that the survival results and top-line response of Phase 1b study evaluating lung cancer treatment with Bristol-Myers Squibb’s drug showed positive signs. The company reported HS-110/Nivolumab Combination for treating non-small cell lung cancer (NSCLC) in Austria at International Association for the Study of...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial.
The data will be...
Evofem Biosciences Inc (NASDAQ:EVFM) recently announced that the clinical findings from its Phase 3 AMPOWER study evaluating Phexxi as contraceptive have been published in a peer-reviewed international journal called Contraception.
The journal published the findings from the AMPOWER study of Phexxi in its website version of the journal. However, it...
Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas.
Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft...
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stated that, subsequent to an autonomous DSMB recommendation and also following futility assessment, it has halted the Phase II HERMIONE trial of “MM-302” in people suffering with +HER2 metastatic breast cancer, but had initially been on regimen of pertuzumab, trastuzumab and ado-trastuzumab emtansine.
The buzz
The decision...
Merck & Co., Inc. (NYSE:MRK) Zovastak, the shingles vaccine developed by Merck has increasingly come under a wave of lawsuits following claims that it is causing serious injury and sometimes even death. Plaintiffs in the lawsuits are now suing Merck for not warning them of the vaccine’s severe side...